Urogen Pharma Ltd
URGN18.870USD
+0.770+4.25%
收盤 09/18, 16:00（美東）報價延遲15分鐘
871.78M總市值
虧損本益比TTM
關於 Urogen Pharma Ltd 公司
UroGen Pharma Ltd. 是一家位於以色列的生物製藥公司。該公司致力於爲癌症和泌尿系統疾病提供解決方案。UroGen 開發了 RTGelTM 逆向熱凝膠，這是一種專有的緩釋水凝膠平臺技術，有可能改善現有藥物的治療效果。其主要候選產品包括 MitoGel 和 VesiGel，採用其專有的逆向熱觸發水凝膠或 RTGel 技術配製而成。MiroGel (UGN-101) 是化療藥物絲裂黴素 C 的緩釋製劑，用於治療低級別上尿路上皮癌，這是一種上尿路上皮癌。VesiGel (UGN-102) 是高劑量絲裂黴素 C 的緩釋製劑，用於治療低級別非肌層浸潤性膀胱癌 (LG-NMIBC)。
公司簡介
公司代碼URGN
公司名稱Urogen Pharma Ltd
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
員工數量235
證券類型Ordinary Share
年結日May 04
公司地址9 Ha'ta'asiya St
城市RA'ANANA
上市交易所NASDAQ Global Market Consolidated
國家Israel
郵編4365007
電話97297707601
網址https://www.urogen.com/
公司代碼URGN
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
業務USD
名稱
營收
佔比
Jelmyto
20.25M
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Jelmyto
20.25M
0.00%
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
持股股東
持股股東
佔比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
股東類型
持股股東
佔比
Hedge Fund
29.41%
Research Firm
21.31%
Investment Advisor/Hedge Fund
20.23%
Investment Advisor
17.86%
Corporation
4.77%
Insurance Company
4.19%
Venture Capital
3.21%
Private Equity
2.11%
Individual Investor
2.09%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
2023Q1
221
19.00M
81.20%
-1.17M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RTW Investments L.P.
3.83M
8.32%
--
--
Mar 31, 2025
TD Securities, Inc.
2.65M
5.75%
+903.36K
+51.65%
Jun 09, 2025
Jefferies LLC
815.00K
1.77%
-150.93K
-15.63%
Mar 31, 2025
Soleus Capital Management, L.P.
2.33M
5.04%
+2.33M
--
Jun 13, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.65%
-50.01K
-2.28%
Mar 31, 2025
SilverArc Capital Management, LLC
1.38M
3%
+260.69K
+23.27%
Mar 31, 2025
Pontifax Venture Capital
1.49M
3.22%
-1.00
-0.00%
Mar 14, 2024
Arkin Communication, Ltd.
1.37M
2.97%
--
--
Feb 22, 2024
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
ARK Israel Innovative Technology ETF
2.21%
ALPS Medical Breakthroughs ETF
0.55%
Tema Oncology ETF
0.43%
Hypatia Women CEO ETF
0.21%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
iShares Russell 2000 Growth ETF
0.04%
查看更多
ARK Israel Innovative Technology ETF
佔比2.21%
ALPS Medical Breakthroughs ETF
佔比0.55%
Tema Oncology ETF
佔比0.43%
Hypatia Women CEO ETF
佔比0.21%
iShares Micro-Cap ETF
佔比0.16%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
Vanguard US Momentum Factor ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.09%
iShares Biotechnology ETF
佔比0.07%
iShares Russell 2000 Growth ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
